Castle Capex To Depreciation vs Days Sales Outstanding Analysis

CSTL Stock

USD 22.72 0.49 2.20%

Trend analysis of Castle Biosciences balance sheet accounts such as Total Assets of 341.8 M, Short and Long Term Debt Total of 15 M or Other Current Liab of 20.7 M provides information on Castle Biosciences' total assets, liabilities, and equity, which is the actual value of Castle Biosciences to its prevalent stockholders. By breaking down trends over time using Castle Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Net Tangible Assets

Build AI portfolio with Castle Stock

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

About Castle Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Castle Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Castle Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Castle Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Castle currently owns. An asset can also be divided into two categories, current and non-current.

Castle Biosciences Balance Sheet Chart

At this time, Castle Biosciences' Net Receivables is quite stable compared to the past year. Common Stock Total Equity is expected to rise to about 30.2 K this year, although the value of Short and Long Term Debt Total will most likely fall to about 15 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Additional Paid In Capital

Add Fundamental

Total Assets

Total assets refers to the total amount of Castle Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Castle Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Castle Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Castle Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Additional Paid In Capital

Additional Paid In Capital (or APIC) is an accounting term found on Castle Biosciences Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x Castle Biosciences Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of Castle Biosciences shares and does not have any impact on the value of APIC. The excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders.

Most indicators from Castle Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Castle Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.Tax Provision is expected to rise to about 3.5 M this year, although the value of Selling General Administrative will most likely fall to about 54.4 M.

	2022	2023	2024	2025 (projected)
Interest Expense	17K	11K	577K	548.2K
Depreciation And Amortization	10.5M	12.3M	16.0M	16.8M

Interest Expense Depreciation And Amortization

Castle Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets
Total Assets		-0.43	0.91	0.93	1.0	0.31	0.97	0.75	0.83	-0.76	-0.8	0.76	0.78	0.84	-0.29	0.7	-0.9	0.96	0.77	0.96	0.97	0.43	-0.24	0.92	0.79	0.96
Short Long Term Debt Total	-0.43		-0.13	-0.15	-0.46	-0.55	-0.51	-0.03	-0.14	0.7	0.1	-0.07	-0.68	-0.21	0.2	-0.44	0.57	-0.55	0.01	-0.37	-0.37	0.24	0.57	-0.3	-0.07	-0.52
Other Current Liab	0.91	-0.13		0.99	0.89	0.08	0.81	0.85	0.75	-0.43	-0.95	0.93	0.45	0.93	-0.29	0.56	-0.8	0.77	0.87	0.86	0.96	0.47	-0.05	0.82	0.91	0.77
Total Current Liabilities	0.93	-0.15	0.99		0.91	0.07	0.84	0.84	0.78	-0.48	-0.94	0.93	0.5	0.91	-0.28	0.54	-0.82	0.8	0.87	0.89	0.95	0.46	-0.12	0.86	0.91	0.8
Total Stockholder Equity	1.0	-0.46	0.89	0.91		0.32	0.98	0.73	0.82	-0.78	-0.78	0.74	0.8	0.82	-0.29	0.7	-0.91	0.97	0.75	0.96	0.96	0.42	-0.28	0.92	0.78	0.97
Other Liab	0.31	-0.55	0.08	0.07	0.32		0.34	-0.04	0.18	-0.57	0.06	-0.08	0.55	0.13	0.15	0.51	-0.32	0.38	-0.06	0.23	0.29	-0.02	0.3	0.21	-0.1	0.45
Net Tangible Assets	0.97	-0.51	0.81	0.84	0.98	0.34		0.63	0.81	-0.87	-0.67	0.66	0.88	0.71	-0.25	0.67	-0.89	1.0	0.66	0.94	0.89	0.37	-0.37	0.91	0.68	0.99
Property Plant And Equipment Net	0.75	-0.03	0.85	0.84	0.73	-0.04	0.63		0.68	-0.27	-0.93	0.77	0.34	0.93	-0.1	0.51	-0.63	0.62	0.98	0.8	0.81	0.58	-0.01	0.75	0.97	0.63
Current Deferred Revenue	0.83	-0.14	0.75	0.78	0.82	0.18	0.81	0.68		-0.63	-0.69	0.63	0.67	0.71	-0.2	0.67	-0.51	0.81	0.77	0.88	0.76	0.78	-0.1	0.89	0.73	0.83
Net Debt	-0.76	0.7	-0.43	-0.48	-0.78	-0.57	-0.87	-0.27	-0.63		0.26	-0.25	-0.99	-0.35	0.07	-0.65	0.7	-0.9	-0.31	-0.73	-0.6	-0.21	0.42	-0.71	-0.31	-0.9
Retained Earnings	-0.8	0.1	-0.95	-0.94	-0.78	0.06	-0.67	-0.93	-0.69	0.26		-0.93	-0.31	-0.97	0.25	-0.49	0.69	-0.64	-0.93	-0.8	-0.88	-0.5	0.09	-0.75	-0.97	-0.63
Accounts Payable	0.76	-0.07	0.93	0.93	0.74	-0.08	0.66	0.77	0.63	-0.25	-0.93		0.27	0.84	-0.17	0.4	-0.68	0.61	0.81	0.73	0.83	0.38	-0.11	0.69	0.89	0.6
Cash	0.78	-0.68	0.45	0.5	0.8	0.55	0.88	0.34	0.67	-0.99	-0.31	0.27		0.4	-0.06	0.66	-0.7	0.91	0.37	0.77	0.62	0.26	-0.42	0.75	0.37	0.91
Non Current Assets Total	0.84	-0.21	0.93	0.91	0.82	0.13	0.71	0.93	0.71	-0.35	-0.97	0.84	0.4		-0.33	0.57	-0.74	0.7	0.92	0.85	0.92	0.49	-0.03	0.79	0.93	0.7
Non Currrent Assets Other	-0.29	0.2	-0.29	-0.28	-0.29	0.15	-0.25	-0.1	-0.2	0.07	0.25	-0.17	-0.06	-0.33		-0.02	0.3	-0.22	-0.08	-0.25	-0.31	0.03	0.31	-0.25	-0.1	-0.18
Other Assets	0.7	-0.44	0.56	0.54	0.7	0.51	0.67	0.51	0.67	-0.65	-0.49	0.4	0.66	0.57	-0.02		-0.51	0.71	0.51	0.6	0.72	0.66	0.03	0.51	0.5	0.7
Long Term Debt	-0.9	0.57	-0.8	-0.82	-0.91	-0.32	-0.89	-0.63	-0.51	0.7	0.69	-0.68	-0.7	-0.74	0.3	-0.51		-0.87	-0.59	-0.81	-0.88	-0.04	0.35	-0.75	-0.65	-0.85
Cash And Short Term Investments	0.96	-0.55	0.77	0.8	0.97	0.38	1.0	0.62	0.81	-0.9	-0.64	0.61	0.91	0.7	-0.22	0.71	-0.87		0.65	0.94	0.87	0.39	-0.37	0.9	0.67	0.99
Net Receivables	0.77	0.01	0.87	0.87	0.75	-0.06	0.66	0.98	0.77	-0.31	-0.93	0.81	0.37	0.92	-0.08	0.51	-0.59	0.65		0.84	0.81	0.66	-0.02	0.81	0.98	0.66
Common Stock Total Equity	0.96	-0.37	0.86	0.89	0.96	0.23	0.94	0.8	0.88	-0.73	-0.8	0.73	0.77	0.85	-0.25	0.6	-0.81	0.94	0.84		0.9	0.49	-0.28	0.99	0.84	0.94
Common Stock Shares Outstanding	0.97	-0.37	0.96	0.95	0.96	0.29	0.89	0.81	0.76	-0.6	-0.88	0.83	0.62	0.92	-0.31	0.72	-0.88	0.87	0.81	0.9		0.44	-0.11	0.83	0.84	0.86
Long Term Debt Total	0.43	0.24	0.47	0.46	0.42	-0.02	0.37	0.58	0.78	-0.21	-0.5	0.38	0.26	0.49	0.03	0.66	-0.04	0.39	0.66	0.49	0.44		0.22	0.47	0.57	0.4
Non Current Liabilities Total	-0.24	0.57	-0.05	-0.12	-0.28	0.3	-0.37	-0.01	-0.1	0.42	0.09	-0.11	-0.42	-0.03	0.31	0.03	0.35	-0.37	-0.02	-0.28	-0.11	0.22		-0.26	-0.12	-0.28
Capital Surpluse	0.92	-0.3	0.82	0.86	0.92	0.21	0.91	0.75	0.89	-0.71	-0.75	0.69	0.75	0.79	-0.25	0.51	-0.75	0.9	0.81	0.99	0.83	0.47	-0.26		0.79	0.92
Inventory	0.79	-0.07	0.91	0.91	0.78	-0.1	0.68	0.97	0.73	-0.31	-0.97	0.89	0.37	0.93	-0.1	0.5	-0.65	0.67	0.98	0.84	0.84	0.57	-0.12	0.79		0.66
Other Current Assets	0.96	-0.52	0.77	0.8	0.97	0.45	0.99	0.63	0.83	-0.9	-0.63	0.6	0.91	0.7	-0.18	0.7	-0.85	0.99	0.66	0.94	0.86	0.4	-0.28	0.92	0.66

Click cells to compare fundamentals

Castle Biosciences Account Relationship Matchups

Castle Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	439.3M	462.6M	447.3M	453.3M	531.2M	341.8M
Other Current Liab	12.1M	19.3M	27.8M	36.3M	39.5M	20.7M
Total Current Liabilities	20.9M	24.9M	36.1M	47.7M	49.4M	28.4M
Total Stockholder Equity	415.7M	411.7M	399.2M	391.3M	455.8M	293.5M
Other Liab	55K	2.8M	19.0M	428K	492.2K	467.6K
Net Tangible Assets	85.1M	415.7M	322.8M	272.8M	313.7M	181.4M
Property Plant And Equipment Net	7.1M	16.9M	26.5M	37.7M	62.7M	65.8M
Net Debt	(409.9M)	(321.6M)	(109.6M)	(83.5M)	(93.4M)	(98.0M)
Retained Earnings	(62.5M)	(93.8M)	(160.9M)	(218.4M)	(200.1M)	(190.1M)
Accounts Payable	2.1M	2.5M	4.7M	10.3M	6.9M	4.3M
Cash	409.9M	329.6M	122.9M	98.8M	119.7M	163.0M
Non Current Assets Total	9.7M	108.8M	155.0M	157.7M	171.1M	179.6M
Non Currrent Assets Other	1.5M	3.0M	(25.6M)	2.6M	2.1M	2.3M
Other Assets	1.0M	2.6M	3.0M	2.2M	2.5M	2.4M
Cash And Short Term Investments	409.9M	329.6M	258.6M	243.1M	293.1M	225.3M
Net Receivables	12.8M	17.3M	23.5M	38.3M	51.2M	53.8M
Common Stock Shares Outstanding	18.9M	25.1M	26.1M	26.8M	29.3M	21.3M
Liabilities And Stockholders Equity	439.3M	462.6M	447.3M	453.3M	531.2M	341.8M
Non Current Liabilities Total	2.8M	25.9M	12.1M	14.4M	26.0M	14.5M
Inventory	2.2M	2.0M	4.0M	7.9M	8.1M	8.5M
Other Current Assets	9.5M	9.6M	6.2M	6.3M	7.7M	6.1M
Other Stockholder Equity	478.2M	505.5M	560.4M	609.5M	655.7M	421.5M
Total Liab	23.6M	50.8M	48.2M	62.1M	75.4M	48.3M
Net Invested Capital	415.7M	411.7M	399.2M	391.3M	465.9M	292.9M
Property Plant And Equipment Gross	7.1M	16.9M	26.5M	45.9M	75.5M	79.3M
Total Current Assets	429.6M	353.7M	292.3M	295.6M	360.2M	257.5M
Accumulated Other Comprehensive Income	(119.7M)	0.0	(381K)	136K	230K	241.5K
Net Working Capital	408.7M	328.9M	256.2M	248.0M	310.8M	229.2M
Common Stock	1.9K	17K	25K	27K	28K	21.0K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet

When determining whether Castle Biosciences is a strong investment it is important to analyze Castle Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Castle Biosciences' future performance. For an informed investment choice regarding Castle Stock, refer to the following important reports:

How To Invest In Castle

Details

Is Castle Stock a good investment?

Details

What is Castle Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.52)

Earnings Share

(0.34)

Revenue Per Share

12.204

Quarterly Revenue Growth

(0.01)

Return On Assets

(0.03)

The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Castle Capex To Depreciation vs Days Sales Outstanding Analysis

About Castle Balance Sheet Analysis

Castle Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Additional Paid In Capital

Castle Biosciences fundamental ratios Correlations

Castle Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Castle Biosciences fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accumulated Amortization	Total Assets
Short Long Term Debt Total	Other Current Liab
Total Current Liabilities	Total Stockholder Equity
Other Liab	Net Tangible Assets
Property Plant And Equipment Net	Total Permanent Equity
Warrants	Current Deferred Revenue
Noncontrolling Interest In Consolidated Entity	Net Debt
Retained Earnings	Accounts Payable
Cash	Non Current Assets Total
Non Currrent Assets Other	Other Assets
Long Term Debt	Cash And Short Term Investments
Net Receivables	Good Will
Common Stock Total Equity	Retained Earnings Total Equity
Common Stock Shares Outstanding	Short Term Investments
Long Term Debt Total	Liabilities And Stockholders Equity
Non Current Liabilities Total	Capital Surpluse
Capital Lease Obligations	Negative Goodwill
Inventory	Other Current Assets
Other Stockholder Equity	Total Liab
Additional Paid In Capital	Deferred Long Term Liab
Net Invested Capital	Preferred Stock Redeemable
Long Term Investments	Property Plant And Equipment Gross
Short Long Term Debt	Preferred Stock Total Equity
Total Current Assets	Accumulated Other Comprehensive Income
Treasury Stock	Non Current Liabilities Other
Accumulated Depreciation	Net Working Capital
Deferred Long Term Asset Charges	Short Term Debt
Intangible Assets	Common Stock
Temporary Equity Redeemable Noncontrolling Interests	Property Plant Equipment
Capital Stock

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Net Tangible Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Other Current Assets	+ 0.99	Net Tangible Assets
Other Current Assets	+ 0.99	Cash And Short Term Investments
Capital Surpluse	+ 0.99	Common Stock Total Equity

Cash	- 0.99	Net Debt
Inventory	- 0.97	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings
Retained Earnings	- 0.95	Other Current Liab
Retained Earnings	- 0.94	Total Current Liabilities
Net Receivables	- 0.93	Retained Earnings